Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
167 hedge funds and large institutions have $752M invested in Clovis Oncology, Inc. in 2019 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 72 increasing their positions, 39 reducing their positions, and 41 closing their positions.
482% more call options, than puts
Call options by funds: $69.7M | Put options by funds: $12M
85% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 39
10% less funds holding
Funds holding: 186 → 167 (-19)
39% less capital invested
Capital invested by funds: $1.24B → $752M (-$487M)
41% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 41
80% less funds holding in top 10
Funds holding in top 10: 5 → 1 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$34.9M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$22.2M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$12M |
| 5 |
SC
Samlyn Capital
New York
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$37.9M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$37.2M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$20M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$19.9M |
| 5 |
O
OrbiMed
New York
|
-$16.6M |
CLVS Hedge Fund Activity: Q2 2019 in Review
167 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2019, worth a combined $752M — down 39% from $1.24B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of CLVS and 24 opened new positions — a net loss of 17 holders — while 39 trimmed existing stakes and 72 added.
The largest buyer was State Street, adding an estimated $34.9M. The largest seller was Armistice Capital, exiting entirely with an estimated $37.9M sold.
- 167 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2019, down from 186 in Q1 2019.
- Funds reported $752M of Clovis Oncology, Inc. stock for Q2 2019, down 39% quarter-over-quarter.
- 24 funds opened new Clovis Oncology, Inc. positions in Q2 2019 and 41 closed out, a net change of -17 holders.
- The largest Clovis Oncology, Inc. buyer in Q2 2019 was State Street, an estimated $34.9M added.
- The largest Clovis Oncology, Inc. seller in Q2 2019 was Armistice Capital, an estimated $37.9M sold.
Based on aggregated 13F filings for Q2 2019.